Lobe Sciences Appoints Dr. Tracy L. Goeken as Chief Medical Officer

VANCOUVER, British Columbia, October 20, 2026 /CourierPR/ -- Lobe Sciences Ltd. has appointed Tracy L. Goeken, M.D., as its Chief Medical Officer, effective October 20, 2026. Goeken brings extensive experience in clinical development and regulatory strategy, particularly in the areas of generalized anxiety disorder and sickle cell disease.

Dr. Goeken most recently served as Chief Medical Officer at Linical, a global clinical research organization, where he led clinical development strategy and medical oversight of clinical trials across multiple therapeutic areas. His appointment is seen as a significant step forward for Lobe Sciences, which is developing therapies for neurological conditions and rare diseases.

Dr. Goeken's background includes more than 20 years of experience in clinical development, regulatory strategy, and medical affairs. He has contributed to regulatory approvals for multiple products across FDA and EMA jurisdictions and has secured EMA acceptance of MRI biomarkers as a primary endpoint in a pivotal multiple sclerosis trial. His clinical development experience includes a Phase 3 generalized anxiety disorder study, Phase 1 sickle cell disease studies, and Phase 2 and Phase 3 migraine and pain studies.

In related news, Lobe Sciences has also engaged Independent Trading Group (ITG) to provide market-making services for its common shares, commencing October 19, 2026. ITG will provide liquidity with the objective of supporting a fair and orderly market, in accordance with applicable securities laws and Canadian Securities Exchange (CSE) policies. The services are not intended to influence the market price of the Company's shares.

Under the agreement, ITG will receive C$6,000 per month, plus applicable taxes. The agreement has an initial term of one month and will automatically renew for successive one-month terms unless terminated by either party on 30 days' notice. The agreement contains no performance-based compensation, and fees are not contingent on the Company's share price or trading volume. No shares or options will be issued as compensation. ITG and the Company are unrelated and unaffiliated entities. At the time of the agreement, neither ITG nor its principals held a direct or indirect interest in the Company's securities.

ITG's address is 33 Yonge Street, Suite 420, Toronto, Ontario M5E 1G4.

Lobe Sciences is a clinical-stage biopharmaceutical company developing therapies for neurological conditions and rare diseases. Its lead neurological candidate, L-130 (Conjugated Psilocin®), is a patented new chemical entity being developed initially for generalized anxiety disorder. L-130 is designed to deliver psilocin directly. Its development program is evaluating whether controlled doses below hallucinogenic levels can provide therapeutic benefit. The Company is also developing S-100, an oral lipid formulation for sickle cell disease.